Annie M Jacobsen1, Jenny N Poynter2,3, Michaela R Richardson2, Phuong L Nguyen4, Betsy Hirsch3,5, Adina Cioc6, Michelle A Roesler2,3, Erica D Warlick1. 1. Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota. 2. Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota. 3. Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. 4. Division of Hematopathology, Rochester, Minnesota. 5. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota. 6. Division of Hematopathology, VA Medical Center, Minneapolis, Minnesota.
Abstract
OBJECTIVE: Little prospective data regarding factors determining patient outcomes in myelodysplastic syndromes (MDS) are available. To establish features of early mortality in MDS, we compare characteristics of patients dying within 1 year of diagnosis with those surviving longer. METHODS: We prospectively enrolled adults with a new MDS diagnosis in a population-based case-control study. Logistic regression was used to calculate odds ratios and 95% confidence intervals for potential predictors of early mortality. Subgroup analyses were conducted within the following groups: high-/very-high-risk IPSS-R; very-low-/low-/intermediate-risk IPSS-R; treated patients; and supportive care only patients. RESULTS: We observed early mortality in those with abnormal cytogenetics (OR: 3.36, 95% CI: 1.52-7.46), three or greater cytogenetic abnormalities (OR: 3.48, 95% CI: 1.51-7.99), treatment at a community medical center (versus academic) (OR: 2.55, 95% CI: 1.18-5.47), and with 2-3 concurrent medical comorbidities (OR: 2.14, 95% CI: 1.08-4.22). Similarly, in subgroup analyses, abnormal cytogenetics remained the main predictor of early mortality. CONCLUSION: Complex cytogenetics and prognostic risk category have been associated with early mortality without intervention. Our data confirm these associations in a large, prospectively followed cohort and highlight the significance of cytogenetic abnormalities and complexity regardless of IPSS-R risk categorization or treatment.
OBJECTIVE: Little prospective data regarding factors determining patient outcomes in myelodysplastic syndromes (MDS) are available. To establish features of early mortality in MDS, we compare characteristics of patients dying within 1 year of diagnosis with those surviving longer. METHODS: We prospectively enrolled adults with a new MDS diagnosis in a population-based case-control study. Logistic regression was used to calculate odds ratios and 95% confidence intervals for potential predictors of early mortality. Subgroup analyses were conducted within the following groups: high-/very-high-risk IPSS-R; very-low-/low-/intermediate-risk IPSS-R; treated patients; and supportive care only patients. RESULTS: We observed early mortality in those with abnormal cytogenetics (OR: 3.36, 95% CI: 1.52-7.46), three or greater cytogenetic abnormalities (OR: 3.48, 95% CI: 1.51-7.99), treatment at a community medical center (versus academic) (OR: 2.55, 95% CI: 1.18-5.47), and with 2-3 concurrent medical comorbidities (OR: 2.14, 95% CI: 1.08-4.22). Similarly, in subgroup analyses, abnormal cytogenetics remained the main predictor of early mortality. CONCLUSION: Complex cytogenetics and prognostic risk category have been associated with early mortality without intervention. Our data confirm these associations in a large, prospectively followed cohort and highlight the significance of cytogenetic abnormalities and complexity regardless of IPSS-R risk categorization or treatment.
Authors: Daniel F Pease; Julie A Ross; Jenny N Poynter; Phuong L Nguyen; Betsy Hirsch; Adina Cioc; Michelle A Roesler; Erica D Warlick Journal: Cancer Epidemiol Date: 2015-02-18 Impact factor: 2.984
Authors: Mikkael A Sekeres; W Marieke Schoonen; Hagop Kantarjian; Alan List; Jon Fryzek; Ronald Paquette; Jaroslaw P Maciejewski Journal: J Natl Cancer Inst Date: 2008-10-28 Impact factor: 13.506
Authors: Rafael Bejar; Kristen E Stevenson; Bennett Caughey; R Coleman Lindsley; Brenton G Mar; Petar Stojanov; Gad Getz; David P Steensma; Jerome Ritz; Robert Soiffer; Joseph H Antin; Edwin Alyea; Philippe Armand; Vincent Ho; John Koreth; Donna Neuberg; Corey S Cutler; Benjamin L Ebert Journal: J Clin Oncol Date: 2014-08-04 Impact factor: 44.544
Authors: Jose F Falantes; Francisco J Márquez-Malaver; Teresa Knight; Cristina Calderón-Cabrera; María L Martino; Jose González; Isabel Montero; Ildefonso Espigado; Jose A Pérez-Simón Journal: Leuk Lymphoma Date: 2016-12-12
Authors: Johanne Rozema; Mels Hoogendoorn; Iris Potma; Inge Ten Seldam; Nic J G M Veeger; Robby E Kibbelaar; Arjan A van de Loosdrecht; Eric N van Roon Journal: EJHaem Date: 2022-03-25